License agreement with Capsant Neurotechnologies (0343I)
08 June 2011 - 4:00PM
UK Regulatory
TIDMATD
RNS Number : 0343I
Asterand PLC
08 June 2011
8 June 2011
ASTERAND PLC
Asterand licenses from Capsant Neurotechnologies Ltd. and
introduces new
3-D human cell based model for diabetes research
Asterand plc (LSE: ATD), a leading provider of human tissue and
cell-based services to pharmaceutical and biotechnology companies
engaged in drug discovery research, today announces the exclusive
licensing on a worldwide basis from Capsant Neurotechnologies Ltd.
and the introduction of isletOrganDOT(TM), a novel 3-D cell based
assay platform for evaluating therapeutic compounds for diabetes.
This new service will be introduced at a podium presentation given
by Samantha Ho, an Asterand Scientist, at the Informa Life Sciences
Cell-Based Assays Conference in Berlin, Germany.
Dr. Thomas Mander, Vice President Sales and Marketing at
Asterand plc noted:
"Following a successful evaluation phase, we are extremely
pleased to have secured an exclusive license from Capsant and to be
launching the isletOrganDOT(TM) system today to add it to our
growing suite of PhaseZERO(R) human-based drug discovery services.
Cell based models for diabetes research have relied on cell lines
or intact rodent and human isolated islets, but both models have
limitations. Asterand's isletOrganDOT(TM) system offers
advancements in functionality, throughput and study design,
allowing us to provide our clients with relevant human data on the
effects of test compounds in a rapid and reproducible manner."
Dr. Graham Place, Senior Department Head Biochemical
Pharmacology at Asterand UK Ltd commented:
"The isletOrganDOT(TM) 3D tissue culture system replicates,
under physiological and pharmacological control, the release of
mediators from human islet cells. Asterand has made a significant
investment to create this innovative, validated and quality
controlled platform. The platform supports human reconstituted
primary islets in a manner that allows cells to retain
functionality for up to 14 days in culture. This feature permits
carefully timed and repeat dosing regimes for test compounds. In
addition, the 24-insert plate format and the ability to run
multiple plates within a single study offers our clients numerous
options for testing batches of early hit compounds through to
in-depth profiling of lead/pre-clinical compounds. We are pleased
to assist our clients in their discovery and development of new
treatments to combat the global health challenge of diabetes."
Asterand's UK service division offers exemplary scientific
expertise in human tissue research. Through its PhaseZERO(R)
platform the Company provides pharmaceutical and biotechnology
companies with compound evaluation, target and biomarker validation
services.
Contacts:
Asterand plc
Martyn Coombs, Chief Executive Officer Tel: + 44 (0) 1763 211
600 /
+ 1 (313) 263-0960
John Stchur, Chief Financial Officer As above
Buchanan Communications
Lisa Baderoon / Mark Court / Isabel Podda Tel: +44 (0) 20 7466
5000
Daniel Stewart & Company plc
Martin Lampshire Tel: +44 (0) 20 7776 6550
About ASTERAND
Asterand plc is a leading supplier of high quality human tissue
and tissue-based services. Our comprehensive approach to human
tissue and research services offers pharmaceutical, biotech and
diagnostic companies the unique opportunity to have one company
meet all of their human biomaterial needs along the continuum of
drug discovery and development. Our mission is to accelerate target
discovery and compound validation and enable pharmaceutical and
biotechnology companies to take safer and more effective drugs into
the market.
For more information, go to www.asterand.com.
About Capsant
Capsant is a company focused on research and development of
commercially viable proprietary organotypic cellular systems with
applications including oncology, neurosciences and
cardiotoxicology.
For more information, go to www.organdotbiosystems.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRFRMFTMBTMBPB
Bioseek (LSE:ATD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Jul 2023 to Jul 2024
